Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.
UCB gets ready for CEO change
Belgian UCB Pharmaceuticals is preparing for a change in leadership. UCB's current executive vice president of biopharma brands and solutions, Jean-Christophe Tellier, will take over as CEO-elect and chairman of the executive committee on March 1 before becoming CEO on Jan. 1, 2015. Tellier replaces current chief Roch Doliveux, who has served as CEO since 2005. Tellier served in management positions at Ipsen and Novartis ($NVS) before joining UCB. Story
|
||||||||||||
Biotech
> Biogen Idec ($BIIB) tapped Stelios Papadopoulos to replace Bill Young as the chairman of the company's board of directors. Release
> Alcobra ($ADHD) has appointed Tomer Berkovitz as chief financial officer. Release
> Exco InTouch appointed Laurence Burke as its vice president of operations. Release
> AlloSource's vice president of R&D and marketing Peter Stevens joined the University of Denver advisory board for the professional sciences master's program in biomedical sciences. Release
> Dr. Bankole Johnson, the scientific founder and chairman of the board of ADial Pharmaceuticals, will head a new Brain Science Research Consortium Unit at the University of Maryland School of Medicine. Release
> Achaogen has appointed Derek Bertocci chief financial officer and John Smither as a member of the board of directors. Release
> Ignyta has appointed Dr. Sara Zaknoen chief medical officer. Release
> Navidea Biopharmaceuticals ($NAVB) has appointed Perry Karsen to the company's board of directors. Release
> Gliknik added Jeffrey Herpst as senior director of clinical development and Dr. Richard Levy to the company's board of directors. Release
Pharma
> Aurinia Pharmaceuticals' chief scientific officer Robert Foster stepped down to pursue other opportunities, according to the company. Release
> Imprimis Pharmaceuticals ($IMMY) named Randle House as the company's vice president of pharmacy operations. Release